SEC Form 4 · accession 0001123343-26-000010
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gary A Lyons
Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 19, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 17, 2026 | M | 5,000 | $17.44 | A | 66,500 | D | |
| Common StockF2 | Aug 17, 2026 | S | 1,900 | $62.5289 | D | 64,600 | D | |
| Common StockF3 | Aug 17, 2026 | S | 2,600 | $63.4999 | D | 62,000 | D | |
| Common StockF4 | Aug 17, 2026 | S | 500 | $64.162 | D | 61,500 | D | |
| Common Stock | Aug 18, 2026 | M | 5,000 | $17.44 | A | 66,500 | D | |
| Common StockF5 | Aug 18, 2026 | S | 4,100 | $63.2659 | D | 62,400 | D | |
| Common StockF6 | Aug 18, 2026 | S | 900 | $63.8557 | D | 61,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F7 | $17.44 | Aug 17, 2026 | M | 5,000 | D | — | May 17, 2027 | Common Stock | 5,000 | 5,000 | D |
| Stock option (right to buy)F7 | $17.44 | Aug 18, 2026 | M | 5,000 | D | — | May 17, 2027 | Common Stock | 5,000 | 0 | D |
Explanation of responses
- F1This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.
- F2The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F3The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F4The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F5The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F6The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F7The stock option is fully vested and exercisable.